Denmark’s Novo Nordisk (NOV: N) has announced new results on NovoSeven (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, at the 58th American Society of Hematology (ASH) annual meeting.
The results show that NovoSeven resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with hemophilia A or B with inhibitors.
Efficacy also remained high for bleeds treated after four hours, showed the sub-analysis of the SMART-7(TM) study on NovoSeven’s efficacy in a real-world setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze